These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 39112932

  • 1. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
    C Willcocks L, Qian W, Cader R, Gatley K, Siddiqui H, Tabebisong E, Champion K, Kronbichler A, Lightstone L, Jayne D, Wilson E, Griffith M.
    BMC Nephrol; 2024 Aug 07; 25(1):253. PubMed ID: 39112932
    [Abstract] [Full Text] [Related]

  • 2. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N.
    BMC Nephrol; 2020 Apr 15; 21(1):134. PubMed ID: 32293308
    [Abstract] [Full Text] [Related]

  • 3. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
    Siligato R, Cernaro V, Nardi C, De Gregorio F, Gembillo G, Costantino G, Conti G, Buemi M, Santoro D.
    Expert Opin Investig Drugs; 2018 Nov 15; 27(11):839-879. PubMed ID: 30360670
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L, Lin Y, Yu B, Wang Y, Pan H, Wang H, Lou X, Lang X, Zhang Q, Jin L, Yang Y, Xiao L, Chen J, Han F.
    Am J Nephrol; 2024 Nov 15; 55(1):25-36. PubMed ID: 37963441
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.
    Kisner T, Burst V, Teschner S, Benzing T, Kurschat CE.
    Nephron Clin Pract; 2012 Nov 15; 120(2):c79-85. PubMed ID: 22286071
    [Abstract] [Full Text] [Related]

  • 7. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
    Health Technol Assess; 2019 May 15; 23(26):1-108. PubMed ID: 31156083
    [Abstract] [Full Text] [Related]

  • 8. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
    Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Maas R, Mayer G, Moiseev S, Muto M, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Segelmark M, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A, RITERM study group.
    Autoimmun Rev; 2020 Nov 15; 19(11):102671. PubMed ID: 32942039
    [Abstract] [Full Text] [Related]

  • 9. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A, König P, Busch M, Wolf G, Mayer G, Rudnicki M.
    Wien Klin Wochenschr; 2013 Jun 15; 125(11-12):328-33. PubMed ID: 23624956
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K.
    BMC Nephrol; 2019 Aug 02; 20(1):293. PubMed ID: 31375087
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
    Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G, Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group.
    J Am Soc Nephrol; 2014 Apr 02; 25(4):850-63. PubMed ID: 24480824
    [Abstract] [Full Text] [Related]

  • 15. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L, Wang W, Wu Y, Xie J, Li X, Pan X, Zhang W, Xu J, Cai Y, Ren H, Chen N.
    Drug Des Devel Ther; 2021 Apr 02; 15():1945-1953. PubMed ID: 34007154
    [Abstract] [Full Text] [Related]

  • 16. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR).
    Yokoyama H, Sugiyama H, Narita I, Saito T, Yamagata K, Nishio S, Fujimoto S, Mori N, Yuzawa Y, Okuda S, Maruyama S, Sato H, Ueda Y, Makino H, Matsuo S.
    Clin Exp Nephrol; 2015 Jun 02; 19(3):496-505. PubMed ID: 25230687
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, Rudnicki M.
    Am J Nephrol; 2014 Jun 02; 39(4):322-30. PubMed ID: 24751753
    [Abstract] [Full Text] [Related]

  • 20. Interventions for focal segmental glomerulosclerosis in adults.
    Hodson EM, Sinha A, Cooper TE.
    Cochrane Database Syst Rev; 2022 Feb 28; 2(2):CD003233. PubMed ID: 35224732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.